Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.

ABSTRACT: Dendritic cell (DC)-based cancer immunotherapy has achieved modest clinical benefits, but several technical hurdles in DC preparation, activation, and cancer/testis antigen (CTA) delivery limit its broad applications. Here, we report the development of immortalized and constitutively activated human primary blood dendritic cell lines (ihv-DCs). The ihv-DCs are a subset of CD11c⁺/CD205⁺ DCs that constitutively display costimulatory molecules. The ihv-DCs can be genetically modified to express human telomerase reverse transcriptase (hTERT) or the testis antigen MAGEA3 in generating CTA-specific cytotoxic T lymphocytes (CTLs). In an autologous setting, the HLA-A2⁺ ihv-DCs that present hTERT antigen prime autologous T cells to generate hTERT-specific CTLs, indu

SUBMITTER: Wu L 

PROVIDER: S-EPMC5948994 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature